- April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as the rate of sustained clinical resolution of symptoms of COVID-19.
- March 29th, 2022 update. Expects to complete full enrollment and to also submit the Study data for 800 subjects.
- February 14th, 2022, update. Trial opens to Turkey with access to 30 sites.
- January 18th, 2022, update. 701 patients dosed to date at 50 sites.
- January 6th, 2022, update. 700 patients participating.
- December 29th, 2022, update. No adverse patient events.
- November 16th, 2022, update. UCSF publishes a promising antiviral effect report.
- October 26th, 2022, update. Safety Review Board supports continuation. Launches 300 parallel patient viral load testing studies (as an antiviral).
- July 15th, 2022. Safety Review Board recommends dosage to increase to 600mg.
- June 8th, 2022. Enters manufacturing discussions with Supriya Lifesciences.
- May 3rd, 2022. Research agreement with the University of California, San Francisco for severe Covid-19.
- March 24th, 2021. Up to 14 clinical sites.
- February 26th, 2021. With $23 million financing sets a goal of 50 clinical sites.
- December 23rd, 2020. Nine clinical sites now participating with an additional six more clinical sites joining the Study in January. Overall enrollment goal of up to 1,000 patients.
- October 26th, 2020. Committed to ten clinical sites across Florida, Texas, Nevada, Arizona, and California.
- September 29th, 2020. Selected and finalized with five clinical sites in Florida, Texas, and California
- September 16th, 2020. Safety Review Board recommends trial to include hospitalized patients with severe COVID-19.
- August 31st, 2020. Receives Independent Review Board ‘protocol’ approval. A protocol is the mechanics of the trial, permitting the trial to launch.
- July 31st, 2020. Revive receives FDA Approval to proceed with Phase III Trial.
#RVVTF
